Why the study?
Does dabigatran improve safety and efficacy for stroke prevention in patients with atrial fibrillation compared to warfarin?
Does dabigatran improve safety and efficacy for stroke prevention in patients with atrial fibrillation compared to warfarin?
This paper reviews the safety and efficacy of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation based on the RE-LY trial.
Offers expert synthesis of RE-LY data for AF; leaves open real-world applicability and long-term safety questions.
Oral anticoagulants such as warfarin have been used widely for the treatment of venous thromboembolism and stroke prevention in atrial fibrillation (AF) patients. Warfarin has significant limitations and also requires frequent monitoring. Thus, there is an unmet need, with the quest for alternative oral anticoagulants with stable pharmacokinetics and pharmacodynamics that do not need monitoring. The paper under evaluation provides us with up-to-date information on the safety and efficacy of a new oral anticoagulant, dabigatran, compared with warfarin for stroke prevention in AF patients.
No takes yet. Share an insight, caveat, or question.
Khoo et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: